2015-2019 Life Science Intermediates Market Consolidation: Who will not survive?

July 2015 | 35 pages | ID: 205458AAEEAEN
Venture Planning Group

Abstracts

Will the industry consolidate, decentralize, or undergo a bimodal transformation?

How will the current trends affect the major market segments?

Which companies will enter the market and which will not survive? This new report from VPGMarketResearch.com provides technological know-how of leading life science intermediates companies. The report presents:

• Internally developed and acquired technologies, and related capabilities.
• Proprietary technologies and patent litigations.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages

Contents

1. BASF

2. CAMBREX

3. CLARIANT

4. DOWPHARMA

5. DSM

6. EVONIK

7. LANXESS

8. LONZA

9. NOVASEP

10. RHODIA

FOR EACH COMPANY, THE REPORT PRESENTS:

Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.